Earlier this week, Pfizer reported that its Phase 3 SigVie-002 trial of sigvotatug vedotin in previously treated non-squamous ...

Pfizer's lung cancer drug trial update, oncology pipeline strategy, Seagen deal impact, and subgroup opportunity in non small ...

Pfizer (PFE) stock drops as CFO Dave Denton will resign Aug. 15; Cecile Guegan is named interim CFO as the company launches ...

Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with ...

Pfizer Inc. PFE shares are trading flat during Wednesday’s premarket session as traders weigh mixed Phase 3 trial headlines ...

Discover top stock picks and new investment opportunities through TipRanks' Smart Investor Newsletter. Pfizer Inc. (PFE) is running a Phase 3 trial titled “A Phase 3, Randomized Double-Blind Trial to ...

Pharmaceutical giants Novo Nordisk (NYSE: NVO) and Eli Lilly (NYSE: LLY) are still the two titans of the weight loss drug ...

Pfizer gains healthcare attention as expanded hemophilia approval broadens treatment use while organizational change shapes ...

Pfizer Inc. said its experimental drug sigvotatug vedotin failed to improve survival in patients with an advanced form of ...

Pfizer Inc. PFE shares are trading lower by almost 1% on Monday as the company shared data from Phase 2b studies of berobenatide, an investigational GLP-1 receptor agonist for weight management.

NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) today announced the decision to discontinue development of danuglipron (PF-06882961), an oral glucagon-like peptide-1 (GLP-1) receptor agonist, ...